Why Houston Has Been the Best-Kept Secret in U.S. Life Sciences - Until Now
In August 2026, Genetic Engineering & Biotechnology News published its first "Next 10 U.S. Biopharma Clusters" list - a ranking of the life sciences hubs emerging outside Boston/Cambridge and the San Francisco Bay Area. Houston came in at number one.
1st Foot USA is based in Houston, and we are proud of it. We also help international companies land in Boston, the Bay Area, and elsewhere, and we have advised clients toward those places when it was the right call. What follows is a view with a home address - not a sales pitch for a zip code.
Our honest reaction to the ranking was not surprise. It was closer to: what took you so long?
Houston did not become a top life sciences cluster in 2026. It became one decades ago. What changed this year is that the rest of the industry finally looked.
The ranking is late
GEN scored emerging regions on five things: patents, NIH funding, venture capital, laboratory space, and life sciences employment. Houston led the country in NIH funding - 2,262 awards totaling $1.25 billion from 2025 through early July 2026 - and ranked second in both life sciences employment, with more than 28,000 jobs, and lab space, at roughly eight million square feet.
None of those numbers are new. The Texas Medical Center was founded in 1945. The funding, the workforce, the lab square footage, and the patent output have been accumulating for most of a century. A ranking published in 2026 is measuring a foundation that was poured long before most of today's biotech investors were born.
Rankings count what is easy to count, after it has already happened. The interesting question is not why Houston scored well. It is why it took until 2026 for anyone to publish the score.
Lilly and Bristol Myers Squibb are the proof, not the cause
Some coverage implies Houston's rise was triggered by big pharma showing up. The investments are real and they are large.
What arrived in Houston
- Eli Lilly announced a $6.5 billion, 236-acre manufacturing facility at Generation Park, expected to create more than 615 full-time jobs.
- Bristol Myers Squibb followed with a $2.3 billion, 600,000-square-foot manufacturing campus and nearly 500 skilled jobs.
- Lilly then acquired Houston biotech startup CrossBridge Bio for up to $300 million.
We read those investments the other way around.
Pharmaceutical site selection is one of the most rigorous, unsentimental processes in global business. Companies of that size evaluate dozens of locations on workforce, land, permitting, logistics, utilities, tax treatment, and proximity to clinical partners. They do not choose a city because a magazine ranked it. Two of the most sophisticated site-selection operations in the world ran that analysis independently and landed in the same place. The investments are evidence of what was already true, not the reason it became true.
A 236-acre pharmaceutical campus is not something you can build in Cambridge, Massachusetts. Houston has land, energy infrastructure, an industrial engineering workforce, and a port. Big pharma noticed before the rankings did.
The numbers are bigger than anyone expects
In our experience, the most common reaction from international life sciences companies arriving in Houston is not "this is nice." It is "we had no idea it was this big."
The Texas Medical Center is the largest medical complex in the world - around 60 institutions on a single campus, including Houston Methodist, MD Anderson Cancer Center, Baylor College of Medicine, Texas Children's Hospital, and UTMB. Hospitals in Houston handle on the order of 10 million patient encounters a year.
For our Nordic clients, one comparison lands harder than any statistic:
That scale changes what is possible. A medtech company that needs 400 patients for a validation study finds them in one city. A digital health company that needs three hospital systems to pilot with can walk between them.
There is a structural reason the scale keeps compounding. TMC's founding deed restrictions require its member institutions to operate as non-profits. Surpluses do not leave for shareholders in another state. They are reinvested - in buildings, research, equipment, and people - here. Run that rule for 80 years across a campus serving 10 million patient encounters annually, and you get something no venture fund could build on purpose.
The people effect
The numbers explain why Houston scored well. They do not explain why Houston works. For that, you have to be here.
Because TMC was built as a single organization with member institutions, the hospitals and research centers here have been part of a community from day one. They compete - for talent, for grants, for patients - and they compete hard. But spend a few weeks on the campus and you notice something: they are primarily competing against other clusters, not against each other. The shared identity is "Houston versus Boston," not "Methodist versus MD Anderson."
That produces an openness that is hard to describe to someone who has not experienced it. Doors open. A researcher at one institution will walk you across the street to a clinician at another because it is good for the cluster. People know people. Bring enough people together who think that way, and it lifts everyone.
In our experience, this is the thing international companies are least prepared for and most grateful for. They arrive expecting the guarded, transactional posture of more established markets. What they find is a genuine willingness to help a newcomer get oriented - from senior clinicians and researchers who have no obvious reason to spend the time.
Our clients have a phrase for it. They say it feels like "only in Texas."
Rankings can measure lab space and NIH dollars. They cannot measure how quickly a stranger gets a meeting. That is where Houston has been number one for a very long time.
Why nobody noticed
If Houston has been this strong for this long, why did it take until 2026 for a national list to say so? Three honest reasons.
Three reasons the story stayed hidden
The energy story crowded out the health story. Ask a European founder what Houston is, and the answer is oil and gas. Fair enough. But it meant the largest medical complex on the planet never made it into most people's mental map of the city.
Biotech's narrative is written on the coasts. The venture capital, the trade press, the conferences, and the celebrated exits have lived in Boston and the Bay Area for decades. Clusters get "discovered" by the people who write about clusters, and those people were not looking south.
Houston was research-and-clinic strong but commercialization-weak. This was a real gap, and pretending otherwise would undercut this article. For years, Houston generated world-class science and clinical capacity but produced fewer venture-backed startups and exits than its research output justified.
That third gap is precisely the one that has closed. BioHouston reports roughly $500 million in venture funding across 2025 and 2026 to date. Rice University's venture studio is spinning out companies like Duracyte. And a $300 million acquisition by Eli Lilly is the kind of exit that makes the next ten founders decide to stay.
The foundation was always here. The commercial layer on top of it is what is new.
What Boston still does better
We would not be credible on Houston if we were not honest about Boston.
Boston/Cambridge remains the deepest ecosystem in the world for venture-backed platform biotech. If your next milestone is a Series B led by a top-tier biotech fund, your board wants investors within walking distance, and your advantage is a novel modality that needs the densest possible concentration of people working on similar science - Boston is still the answer, and we will tell you so. It also has a longer track record of exits, a deeper pool of experienced biotech executives, and a concentration of specialized service providers that Houston is still building.
None of that diminishes Houston. It clarifies what Houston is: a different kind of cluster with a different center of gravity - patients and clinicians rather than venture funds. For a large share of international life sciences companies, that is the center of gravity that matters.
Who Houston is right for
For an international life sciences or healthtech company deciding where to put its first U.S. foot, Houston tends to be the strongest choice when one or more of the following is true.
Five signs Houston is the right landing spot
Your next milestone is clinical, not financial. Validation studies, pilots with health systems, real-world evidence, rare-disease patient access. Houston's scale is the advantage here.
You will eventually manufacture in the U.S. Land, industrial workforce, energy infrastructure, and a port. Lilly and BMS have already made the case.
You are medtech, diagnostics, or digital health rather than platform biotech. Proximity to clinicians and hospital buyers matters more than proximity to venture funds.
Cost matters. Lab space, housing, and salaries are materially lower than the coasts, and Texas has no state income tax - which affects both your budget and your ability to recruit.
You are coming from abroad. Houston is one of the most international cities in the country, with two international airports, direct flights to Europe and Asia, and a long habit of welcoming companies from elsewhere.
Houston is the wrong call when your business is fundamentally a venture-driven platform play whose value depends on the Boston investor network. That is not a weakness. It is a difference.
Final thought
Houston did not change in 2026. A ranking was published, two pharmaceutical giants broke ground, and the industry's attention finally caught up with what has been sitting on a 1,300-acre campus in south Houston for 80 years.
We have been here the whole time. We know the people in these buildings, we know what they will do for a newcomer who shows up with real science and real intent, and we know the numbers are bigger than anyone expects until they see them.
The secret is out. That is good for Houston. It is also very good for the international companies that arrive next.
If your company is in life sciences, medtech, or digital health and is weighing where to land in the U.S. - Houston, Boston, or somewhere else - that is a decision worth making with someone who knows more than one of those cities from the inside. 1st Foot USA helps international healthcare and life sciences companies choose the right landing spot, open the right doors, and get their first U.S. foot on solid ground. Explore our Healthcare & Life Sciences practice or book a discovery call.